Instem Completes Acquisition of Xybion Digital, Reinforcing Leadership in Preclinical R&D
In a landmark move for the life sciences industry, Instem has officially announced the acquisition of Xybion Digital (“Xybion”), solidifying its position as a leader in preclinical research and drug safety testing. Known for its cutting-edge PristimaTM platform, Xybion brings decades of expertise in supporting preclinical R&D and regulatory submissions, making this acquisition a strategic leap forward for both companies.
Founded in 1977, Xybion has long been a trusted partner for pharmaceutical companies, contract research organizations (CROs), and biotechnology firms. Its flagship product, PristimaTM, is an advanced cloud-based Software-as-a-Service (SaaS) study management platform tailored to facilitate Good Laboratory Practice (GLP)-compliant preclinical research. Beyond PristimaTM, Xybion also offers solutions in the Laboratory Information Management System (LIMS) space through its AutoscribeTM brand, Quality Management Systems (QMS) under the Xybion QMSTM suite, and advisory services for regulated environments. These offerings have enabled Xybion to serve a global clientele, with active customers spanning over 30 countries across five continents.
The journey of Xybion’s growth took a significant turn in 2008 when it was acquired by Banerjee Group LLC, led by Dr. Pradip K. Banerjee, a veteran executive in life sciences R&D and the founding managing partner of Accenture’s life sciences R&D business. Under Banerjee Group LLC’s leadership, Xybion expanded its portfolio through acquisitions of Amadeus solutions, Stelex, Vital Path from GE Healthcare, and Autoscribe Informatics. This strategic consolidation positioned Xybion as a comprehensive provider of software and consulting services for regulated industries, particularly in preclinical research.
For Instem, the acquisition represents a transformative milestone that enhances its capabilities and broadens its reach within the life sciences sector. By integrating Xybion’s robust solutions and experienced team, Instem now stands as a powerhouse in preclinical study management, equipped to meet the diverse needs of its clients. The combined entity will leverage shared expertise to drive innovation, deliver superior customer experiences, and accelerate research programs for its global customer base.
“This acquisition effectively creates a ‘new Instem’ in the preclinical R&D space—a leader with unparalleled scale and talent,” said Vik Krishnan, CEO of Instem. “Our mission has always been to help our customers make discoveries and advance their research programs. With Xybion joining us, we can now dedicate even more resources to innovation while continuing to delight our customers. This is truly a transformational moment for the field of preclinical life sciences R&D.”
Krishnan also extended a warm welcome to Xybion’s employees, expressing enthusiasm about the collaboration ahead. “I am thrilled to welcome Xybion’s talented team to Instem. Together, we are poised to tackle complex R&D challenges in the highly regulated GLP environment,” he added.
One of the most compelling aspects of this acquisition is the addition of Xybion’s extensive customer base, which includes many large and industry-leading pharmaceutical and CRO organizations. These new partnerships not only expand Instem’s footprint but also reinforce its reputation as a trusted provider of end-to-end solutions for preclinical R&D. With the integration of Xybion’s workforce, Instem gains access to a wealth of knowledge and experience that will further enhance its ability to serve clients effectively.
The merger also underscores Instem’s commitment to addressing the evolving needs of the life sciences community. As regulatory requirements become increasingly stringent and technological advancements continue to reshape the industry, having a comprehensive suite of tools and services is essential. By combining Instem’s existing offerings with Xybion’s specialized platforms like PristimaTM and AutoscribeTM, the company is better positioned than ever to support its customers throughout the entire preclinical development lifecycle.
Looking ahead, the synergy between Instem and Xybion promises to unlock new opportunities for growth and innovation. Both companies share a common vision of empowering researchers to bring groundbreaking therapies to market faster and more efficiently. With their combined strengths, they are well-equipped to navigate the complexities of modern R&D and deliver value to their global clientele.
About Instem
Instem is a leading supplier of SaaS platforms across Discovery, Study Management, Regulatory Submission and Clinical Trial Analytics. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.
Founded in the United Kingdom in 1969, Instem has deep roots internationally across North America, EMEA and APAC. Instem maintain a commercial and technical presence throughout these regions and pride ourselves on localized support for our diverse client base. Instem has been an ARCHIMED company since 2023.
